Download as PPSX, PPTX
Uploaded byDomina Petric
Types of insulin
This document discusses different types of insulin, including rapid-acting, long-acting, and premixed analogs. Rapid-acting analogs like insulin lispro and insulin aspart have a faster onset and shorter duration than regular human insulin. Long-acting analogs such as insulin glargine, insulin detemir and insulin degludec are designed to provide basal insulin levels for 24 hours or more with less variability than NPH insulin. Premixed analogs contain both rapid- and long-acting components. The document also briefly mentions new methods of insulin delivery under development.
More Related Content
![Drug presentation (Lactulose) [Constipation]](https://cdn.slidesharecdn.com/ss_thumbnails/drugpresentation-150827081243-lva1-app6891-thumbnail.jpg?width=640&height=640&fit=bounds)
Similar to Types of insulin
![diabetes.pptxgtgthtgtgtgthyjiulp'][pp0ppp](https://cdn.slidesharecdn.com/ss_thumbnails/diabetes-250824142109-beeb6b11-thumbnail.jpg?width=640&height=640&fit=bounds)
More from Domina Petric
Types of insulin
- 1. Types of insulin DominaPetric, MD
- 2. Introduction Insulin can notbe taken as a pill: stomach acid would destroy it. Insulin is taken as a subcutaneous injection.
- 3. Rapid acting insulinanalogs • Regular human insulin comes as a hexamer in solution. • Upon subcutaneous application there is a delay in action due to dissociation and resorption. • Peak plasma concentrations are reached 45-120 minutes after the application. • Such insulinemic profile does not reproduce the dynamics of endogenous insulin secretion in healthy individuals after β cell stimulation.
- 4. Rapid acting insulinanalogs • An interval of at least 15 minutes between the application and meal is mandatory. • Snacks between meals are needed to avoid postprandial hypoglycemia due to prolonged insulin action. • Ideal rapid acting insulin would have the peak action after 30-60 minutes and rapid return to basal levels after 180 minutes.
- 5. Rapid acting insulinanalogs Insulin lispro Insulin aspart
- 6. Rapid acting insulinanalogs Insulin lispro • In the insulin lispro molecule, the sequence of 28th and 29th molecule is inversed: proline-lysine into lysine-proline. • This inversion results in modification of the conformation of the insulin molecule, which becomes more similar to insulin like growth factor 1 (IGF-1) molecule. • The affinity to form dimers and hexamers decreases.
- 7. Rapid acting insulinanalogs Insulin lispro • The pharmacokinetics of insulin lispro is more similar to the insulin response in healthy individuals. • The rise in insulin concentration is faster and peak concentrations are higher than with regular insulin. • Insulin lispro can better manage postprandial hyperglycemia than regular human insulin without increasing the risk of hypoglycemia.
- 8. Rapid acting insulinanalogs Insulin lispro • Postprandial hyperglycemia is contributing to the metabolic regulation in general, but it is also an independent risk factor for cardiovascular morbidity and mortality. • With insulin lispro hypoglycemia occurs most frequently about 90 minutes upon application. • Regular insulin usually causes late hypoglycemia.
- 9. Rapid acting insulinanalogs Insulin lispro • The IGF-1 receptor affinity of insulin lispro is increased as compared with regular insulin. • More rapid progression of diabetic retinopathy was observed in few pregnant diabetic patients using insulin lispro. • From the patient´s point of view, the principal advantages of insulin lispro are application immediately before the meal and less hypoglycemias.
- 10. Rapid acting insulinanalogs Insulin aspart • In the insulin aspart molecule, the 28th aminoacid of B-chain proline is substituted for aspartate. • The charge of the molecule is changed and the affinity for self-association decreased. • Insulin aspart has a slightly longer duration of action than insulin lispro. • Glucose escape is less pronounced. • IGF-1 receptor affinity and mitogenic potential are similar to those of human insulin.
- 11.
- 12.
- 13. Long-acting insulin analogs •Human insulin preparations with prolonged action are aimed to cover the basal insulin requirements: fasting and between the meals. • NPH (neutral protamine Hagedorn) and zinc-insulin are two basic types of long-acting analogs. Both of them are associated with two major problems: • suspensions (mixing prior to use is critical, possibility of mistake) • significant inter- and intraindividual differences in the absorption rates and bioavailability
- 14. Long-acting insulin analogs •Neither NPH nor zinc-insulin preparations can cover the basal insulin needs for entire 24 hours. • In the multiple injection therapy regimen with regular insulin, the prolonged action of regular insulin also covers the basal insulin needs between the meals during the day. • With the advent of new and shorter-acting insulin analogs the necessity for more than one dose of basal insulin has emerged.
- 15. Long-acting insulin analogs •The peak action of NPH insulin is 5-7 hours after the application. • If the evening dose is given at bedtime (around 10 p.m.), the peak action will be between 3 and 5 a.m., when the need for insulin is lowest: high risk of hypoglycemia. • In patients with type I diabetes treated with multiple injection therapy, about 50% of all hypoglycemic episodes occur during the night.
- 16. Long-acting insulin analogs •Between 5 and 8 a.m. insulin sensitivity decreases and so does insulin concentration: dawn phenomenon. • The dawn phenomenon (dawn effect) is the term used to describe an abnormal early- morning increase in blood sugar (glucose), usually between 2 a.m. and 8 a.m., in people with diabetes.
- 17. Long-acting insulin analogs •The natural overnight release of the counter- regulatory hormones, including growth hormone, cortisol, glucagon and epinephrine, increases insulin resistance, causing blood sugar to rise. • High morning blood sugar may also be caused by insufficient insulin the night before, insufficient anti-diabetic medication dosages or carbohydrate snack consumption at bedtime.
- 18. Long-acting insulin analogs Insulinglargin • The molecule of glargine has isoelectric point of pH 6,7 in contrast to pH 5,4 of human insulin. • Modification has been made on the C-terminal end of B-chain, where two arginine molecules are added. • Glycine on A-21 position is substituted by arginine. • The pH of the preparation is 4,0: at this pH glargine is completely soluble.
- 19. Long-acting insulin analogs Insulinglargin • At a more neutral pH of the tissue, microprecipitation takes place, which delays resorption. • Resorption is also additionally delayed with a small amount of zinc added. • Glargine has the same affinity for insulin receptor as human insulin. • The affinity for IGF-1 receptor is 3-14 times greater.
- 20. Long-acting insulin analogs Insulinglargin • After subcutaneous application glargine reaches its maximum activity after 4-5 hours, which then remains even without pronounced peaks. • Patients receiving glargine may have less nocturnal hypoglycemias, less symptomatic hypoglycemias and less severe hypoglycemia than with NPH.
- 21. Long-acting insulin analogs Insulindetemir • In the detemir molecule, the threonine on B30 position is removed. • Myristoyl fatty acid is acylated to lysine at B29. • Prolonged action is probably due to a combination of hexamer formation and reversible albumin binding. • About 98% of detemir in plasma is bound to albumin. • Only the free fraction can activate insulin receptor.
- 22. Long-acting insulin analogs Insulindetemir • Detemir is soluble at neutral pH and subcutaneous depot remains in soluble state, which makes the resorption surface larger and diminishes resorption variability. • Detemir has a lower receptor affinity than human insulin. • It has even lower IGF-1 affinity and mitogenic potential.
- 23. Long-acting insulin analogs Insulindetemir Detemir has a lower intraindividual pharmacokinetic variability than NPH insulin. Detemir also has a relatively stronger effect on the liver than on peripheral tissues.
- 24. Long-acting insulin analogs Insulindegludec • Ultralong-acting basal insulin analog. • Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.
- 25. Long-acting insulin analogs Insulindegludec • It is administered via subcutaneous injection once daily. • It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).
- 26. Premixed insulin analogs Low-mixturepreparations contain 25-50% of rapid-acting component. High-mixtures contain 75% of rapid- acting component.
- 27.
- 28. New methods ofinsulin delivery enteral insulin oral insulin with nanoparticles transdermal insulin artificial beta cell prototype
- 29. Literature • Novak B.Metelko Ž. New trends in insulin therapy. Diabetologia Croatica 2003;32-2. • Medicineonline.com • Rxlist.com • Mayoclinic.org • www.rn.com